Top Stories
The collaboration will explore use cases that could improve clinical-trial efficiency, including identifying eligible patients earlier and easier, across several disease areas.
PacBio's HiFi sequencing can detect complex genetic variants and structural changes that shorter-read methods may miss, offering researchers a more detailed view of disease biology.
The partners will use generative and predictive AI to refine the lipid components of drug-carrying nanoparticles, although specific disease targets have yet to be disclosed.
The automated insulin delivery system was originally cleared for type 1 diabetes in 2024.
Some cell and gene therapy processing platforms will be banned from exportation, while target-discovery related technologies may be exported if given a regulatory green light.
Conference News
Nabsys's Alka Chaubey, Ph.D., to present preliminary data on Electronic Genome Mapping in hematologic malignanciesPROVIDENCE, R.I., Oct. 19, 2026 /PRNewswire/ -- Nabsys 2.0, LLC ("Nabsys") today annou...
ESMO 2026 results highlight prospective deployment of VTrial™ in an active oncology trial to support efficacy endpoints, including AI-assisted RECIST 1.1 assessmentCAMBRIDGE, Mass., Oct. 20, 2026 /PRN...
MenoZen VRTM successfully delivers cognitive behavior therapy in small study, effectively overcoming access barriers to more traditional evidence-based therapiesCLEVELAND, Ohio (October 20, 2026)—Cogn...
Leading institutions will evaluate StarGuide GXi across quantitative imaging, dynamic imaging and emerging theranostic applicationsClinical experience from more than 1,000 patient studies was establis...
October 20, 2026 – 5:45 pm CESTMedian Technologies and its U.S. subsidiary eyonis Inc. will present eyonis® LCS at this landmark meeting of the international lung cancer screening communityI-ELCAP has...
